select a format

Single User License
USD 2000 INR 129580
Site License
USD 4000 INR 259160
Corporate User License
USD 6000 INR 388740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Pertussis Whooping Cough-Pipeline Review, H1 2016

Pertussis Whooping Cough-Pipeline Review, H1 2016


  • Products Id :- GMDHC8170IDB
  • |
  • Pages: 104
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Pertussis (Whooping Cough)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Pertussis (Whooping Cough)-Pipeline Review, H1 2016', provides an overview of the Pertussis (Whooping Cough) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough)

The report reviews pipeline therapeutics for Pertussis (Whooping Cough) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pertussis (Whooping Cough) therapeutics and enlists all their major and minor projects

The report assesses Pertussis (Whooping Cough) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pertussis (Whooping Cough)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Therapeutics Development 11

Pipeline Products for Pertussis (Whooping Cough)-Overview 11

Pipeline Products for Pertussis (Whooping Cough)-Comparative Analysis 12

Pertussis (Whooping Cough)-Therapeutics under Development by Companies 13

Pertussis (Whooping Cough)-Therapeutics under Investigation by Universities/Institutes 16

Pertussis (Whooping Cough)-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Pertussis (Whooping Cough)-Products under Development by Companies 20

Pertussis (Whooping Cough)-Products under Investigation by Universities/Institutes 22

Pertussis (Whooping Cough)-Companies Involved in Therapeutics Development 23

Beijing Minhai Biotechnology Co., Ltd 23

Beijing Tiantan Biological Products Co., Ltd. 24

Bharat Biotech International Limited 25

Biological E. Limited 26

Boryung Pharmaceutical Co., Ltd. 27

Daiichi Sankyo Company, Limited 28

DBV Technologies S.A. 29

GlaxoSmithKline Plc 30

Green Cross Corporation 31

ILiAD Biotechnologies, LLC 32

Indian Immunologicals Limited 33

LG Life Science LTD. 34

NanoBio Corporation 35

Panacea Biotec Limited 36

Sanofi Pasteur SA 37

Serum Institute of India Limited 38

Sinovac Biotech Ltd. 39

Synthetic Biologics, Inc. 40

Zydus Cadila Healthcare Limited 41

Pertussis (Whooping Cough)-Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Combination Products 43

Assessment by Target 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole-cell) + tetanus) (pentavalent) vaccine-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

(diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

(diphtheria + pertussis (whole cell) + tetanus) vaccine-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

(diphtheria + pertussis (whole-cell) + tetanus) vaccine-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

(diphtheria + tetanus + pertussis (acellular)) vaccine-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

(hepatitis B + pertussis) vaccine-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

bladder cancer + pertussis + tuberculosis vaccine-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

diphtheria + pertussis(acellular) + tetanus vaccine-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Eupenta-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

GC-3111A-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

LBVD-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

pertussis (acellular) vaccine-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

pertussis (acellular) vaccine-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

pertussis (acellular) vaccine-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

pertussis (whole-cell) vaccine-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

pertussis [strain BPZE1] vaccine-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

pertussis vaccine-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

pertussis vaccine-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

pertussis vaccine-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

SYN-005-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

VN-0103-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

VN-0105-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Pertussis (Whooping Cough)-Dormant Projects 91

Pertussis (Whooping Cough)-Discontinued Products 92

Pertussis (Whooping Cough)-Product Development Milestones 93

Featured News & Press Releases 93

Mar 21, 2016: BE Receives an Order from Govt. of India to Supply Liquid Pentavalent Vaccines 93

Oct 21, 2015: Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough 93

Jun 10, 2015: Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine 94

Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis) 95

Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta 96

Mar 02, 2015: Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015 96

Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 97

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteurs Investigational Pediatric Hexavalent Vaccine 97

Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 98

Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program 98

Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 99

Aug 12, 2014: Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC 100

Jul 21, 2014: Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough at Gordon Research Conference 100

Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic 101

Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 102

Appendix 103

Methodology 103

Coverage 103

Secondary Research 103

Primary Research 103

Expert Panel Validation 103

Contact Us 103

Disclaimer 104

List of Figures

Number of Products under Development for Pertussis (Whooping Cough), H1 2016 11

Number of Products under Development for Pertussis (Whooping Cough)-Comparative Analysis, H1 2016 12

Number of Products under Development by Companies, H1 2016 13

Number of Products under Investigation by Universities/Institutes, H1 2016 16

Comparative Analysis by Late Stage Development, H1 2016 17

Comparative Analysis by Clinical Stage Development, H1 2016 18

Comparative Analysis by Early Stage Products, H1 2016 19

Assessment by Monotherapy Products, H1 2016 42

Assessment by Combination Products, H1 2016 43

Number of Products by Targets, H1 2016 44

Number of Products by Stage and Targets, H1 2016 44

Number of Products by Routes of Administration, H1 2016 46

Number of Products by Stage and Routes of Administration, H1 2016 46

Number of Products by Top 10 Molecule Types, H1 2016 48

Number of Products by Stage and Top 10 Molecule Types, H1 2016 48

List of Tables

Number of Products under Development for Pertussis (Whooping Cough), H1 2016 11

Number of Products under Development for Pertussis (Whooping Cough)-Comparative Analysis, H1 2016 12

Number of Products under Development by Companies, H1 2016 14

Number of Products under Development by Companies, H1 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2016 16

Comparative Analysis by Late Stage Development, H1 2016 17

Comparative Analysis by Clinical Stage Development, H1 2016 18

Comparative Analysis by Early Stage Development, H1 2016 19

Products under Development by Companies, H1 2016 20

Products under Development by Companies, H1 2016 (Contd..1) 21

Products under Investigation by Universities/Institutes, H1 2016 22

Pertussis (Whooping Cough)-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 23

Pertussis (Whooping Cough)-Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016 24

Pertussis (Whooping Cough)-Pipeline by Bharat Biotech International Limited, H1 2016 25

Pertussis (Whooping Cough)-Pipeline by Biological E. Limited, H1 2016 26

Pertussis (Whooping Cough)-Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 27

Pertussis (Whooping Cough)-Pipeline by Daiichi Sankyo Company, Limited, H1 2016 28

Pertussis (Whooping Cough)-Pipeline by DBV Technologies S.A., H1 2016 29

Pertussis (Whooping Cough)-Pipeline by GlaxoSmithKline Plc, H1 2016 30

Pertussis (Whooping Cough)-Pipeline by Green Cross Corporation, H1 2016 31

Pertussis (Whooping Cough)-Pipeline by ILiAD Biotechnologies, LLC, H1 2016 32

Pertussis (Whooping Cough)-Pipeline by Indian Immunologicals Limited, H1 2016 33

Pertussis (Whooping Cough)-Pipeline by LG Life Science LTD., H1 2016 34

Pertussis (Whooping Cough)-Pipeline by NanoBio Corporation, H1 2016 35

Pertussis (Whooping Cough)-Pipeline by Panacea Biotec Limited, H1 2016 36

Pertussis (Whooping Cough)-Pipeline by Sanofi Pasteur SA, H1 2016 37

Pertussis (Whooping Cough)-Pipeline by Serum Institute of India Limited, H1 2016 38

Pertussis (Whooping Cough)-Pipeline by Sinovac Biotech Ltd., H1 2016 39

Pertussis (Whooping Cough)-Pipeline by Synthetic Biologics, Inc., H1 2016 40

Pertussis (Whooping Cough)-Pipeline by Zydus Cadila Healthcare Limited, H1 2016 41

Assessment by Monotherapy Products, H1 2016 42

Assessment by Combination Products, H1 2016 43

Number of Products by Stage and Target, H1 2016 45

Number of Products by Stage and Route of Administration, H1 2016 47

Number of Products by Stage and Molecule Type, H1 2016 49

Pertussis (Whooping Cough)-Dormant Projects, H1 2016 91

Pertussis (Whooping Cough)-Discontinued Products, H1 2016 92

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

Bharat Biotech International Limited

Biological E. Limited

Boryung Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

DBV Technologies S.A.

GlaxoSmithKline Plc

Green Cross Corporation

ILiAD Biotechnologies, LLC

Indian Immunologicals Limited

LG Life Science LTD.

NanoBio Corporation

Panacea Biotec Limited

Sanofi Pasteur SA

Serum Institute of India Limited

Sinovac Biotech Ltd.

Synthetic Biologics, Inc.

Zydus Cadila Healthcare Limited

Pertussis (Whooping Cough) Therapeutic Products under Development, Key Players in Pertussis (Whooping Cough) Therapeutics, Pertussis (Whooping Cough) Pipeline Overview, Pertussis (Whooping Cough) Pipeline, Pertussis (Whooping Cough) Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com